Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493153 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29398074 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29552281 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29400538 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30695566 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119866 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29398455 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119859 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8656057 | 0.90 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL14029674 | 0.89 | MDM4 (0.48) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731306-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-116554126-B | Compound for targeted degradation of CDK6 and application thereof | 兰州大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| WO-2025003147-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-02 | — | — | WO | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| EP-4232578-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH Zurich (CH) | 2023-08-30 | — | — | EP | disclosed |
| CN-116554126-A | Compound for targeted degradation of CDK6 and application thereof | 兰州大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-114783546-A | Combined chemical molecule database CCSMD for screening anticancer active small molecules and application thereof | 兰州大学 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022084486-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH ZURICH (CH) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | MDM4 455/4885TP53 8/4885CASP3 2833/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | MDM4 2014/4885TP53 119/4885CASP3 2086/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | MDM4 2510/4885TP53 112/4885CASP3 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.